

# PRELIMINARY PROGRAMME

---

**Diabetesity & EuReCa-M**

**SAVE THE DATE**

## **2026 Diabetesity & EuReCa-M joint CME course**

April 24-25, 2026

Barcelona, Spain



---

### **Preliminary Programme**

**Joint Event by Diabetesity & EuReCa-M Working Groups of the ERA –  
European Renal Association**

***Obesity, Kidney Disease, and Cardiovascular Risk: From Knowledge to Action***

## Day 1 – Afternoon

### 16:00 – 16:30 | Welcome and Opening Remarks

President of ERA. [Roser Torra](#)

Chairs of EURECAm and DIABESITY. [Jose M Valdivielso](#) and [Enrique Morales](#)

### 16:30 – 17:30 | Session 1 – Obesity and Kidney Disease: A Complex Relationship

Chairs: [Enrique Morales](#) and [Liffert Vogt](#)

- Why do only some people with obesity develop CKD? [Trond Geir Jenssen](#)
- The role of obesity in other nephropathies [Matias Trillini](#)
- Commentary on the KDIGO obesity guidelines [Morten Buus Jørgensen](#)

### 17:30 – 18:30 | Session 2 – Pathophysiological Crosstalk: Obesity–Kidney–Heart

Chairs: [Ana Elena Rodriguez-Rodriguez](#) and [Patrick Mark](#)

- Renal bioenergetics in obesity. [Esteban Porrini](#)
- Cardiovascular consequences of metabolic disease in CKD. [Liffert Vogt](#)
- From animals to humans: renoprotection in diabetic nephropathy. [Johannes Stegbauer](#)

---

## Day 2 – Morning

### 09:00 – 10:00 | Session 3 – Cardiovascular Risk Assessment in CKD

Chairs: [William Martin](#) and [Fotini Iatridi](#)

- Risk stratification beyond the Framingham model. [Jose M Valdivielso](#)
- Vascular aging in diabetic CKD. [Nejc Piko](#)
- Dual Organ Defense: SGLT2i for Cardiovascular Protection in Diabetic CKD. [Shanmugakumar Chinnappa](#)

### 10:00 – 11:00 | Session 4 – Emerging Treatments in the Cardio-Renal-Metabolic Syndrome

Chairs: [Beatriz Fernández-Fernández](#) and [Marieta Theodorakopoulou](#)

- CKM syndrome: an American invention or a useful global concept? [Sebastian Bevc](#)
- SGLT2i to the Rescue: A New Era for CKD, Heart Failure & Diabetes. [Patrick Mark](#)
- Cardioprotective antihypertensives in diabetic kidney disease. [Fotini Iatridi](#)

## 11:00 – 11:30 | Coffee Break

## 11:30 – 12:30 | Session 5 – Managing Obesity in CKD: What's New?

Chairs: *Evangelia Ntounousi* and *Morten Buus Jørgensen*

- Old and new therapies for obesity in CKD. *Marieta Theodorakopoulou*
- Do very low-calorie diets have a role? *Manuela Abbate*
- Knowns and unknowns of GLP-1 receptor antagonists therapy in obesity-related CKD. *Marius Miglinas*

## 12:30 – 13:30 | Lunch

---

## Day 2 – Afternoon

## 13:30 – 14:30 | Session 6 – Obesity in Dialysis and Transplant: New Perspectives

Chairs: *Shanmugakumar Chinnappa* and *Matias Trillini*

- Does reverse epidemiology of BMI in dialysis still hold true? *Claudia Torino*
- The role of GLP-1 receptor agonists in CKD in obese patients. *Beatriz Fernández-Fernández*
- Bariatric surgery vs GLP-1RA: pros and cons. *Enrique Morales*

## 14:30 – 15:30 | Session 7 – Non-Pharmacological Interventions: How Far Can They Go?

Chairs: *Marius Miglinas* and *Johannes Stegbauer*

- Lifestyle interventions: real impact. *Evangelia Ntounousi*
- Synergies between diet, exercise, and pharmacotherapy. *Amaryllis Van Craenenbroeck*
- Prevention of CKD: The Strong Kidney Taskforce. *Charles J Ferro*

## 15:30 – 16:30 | Session 8 – Interactive Case Discussion

Chairs: *Amaryllis Van Craenenbroeck* and *Trond Geir Jenssen*

- Clinical cases-Complex patient with cardio-reno-metabolic syndrome. *Justo Sandino, Marina López y Clara Barrios*

---

**16:30 – 17:30 | Session 9 – Closing Joint Roundtable: Integration and Controversies**

Chairs: **Sebastjan Bevc** and **Claudia Torino**

- SEN, SLANH and SEEDO Consensus report on Obesity related kidney diseases. *Maria José Soler*
- Identifying knowledge gaps and future directions. *Pantelis Sarafidis*

**17:30 – 18:00 | Closing Remarks.** **Jose M Valdivielso** and **Enrique Morales**

**19:30 | Closing Dinner** (*Venue to be announced*)

### Diabetesity Board Members

- **Enrique Morales (Chair),** Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain
- Matias Trillini (Vice-Chair), Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
- Sebastjan Bevc, Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia
- Trond G. Jenssen, Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital Rikshospitalet, Oslo, Norway
- William Martin, Department of Nephrology, Mater Misericordiae University Hospital, Dublin, Ireland
- Ana Elena Rodriguez-Rodriguez, Laboratory of Renal Function, Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain
- Marieta Theodorakopoulou, First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Marius Miglinas, Center of Nephrology, Santaros Klinikos, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- Morten Buus Jørgensen, Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen, Denmark

### EuReCa-M Board Members

- **Jose M. Valdivieso (Chair), Vascular and Renal Translational Research Group,** IRBLleida, Lleida, Spain
- Patrick Mark (Vice-Chair), School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
- Shanmugakumar Chinnappa, Department of Nephrology, Doncaster and Bassetlaw Teaching Hospitals NHS Trust, Doncaster, UK
- Beatriz Fernández-Fernández, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain
- Fotini Iatridi, First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Evangelia Ntounousi, Nephrology Department, School of Health Sciences, University of Ioannina and University Hospital of Ioannina, Ioannina, Greece.
- Liffert Vogt, Department of Internal Medicine, Section of Nephrology, Amsterdam, The Netherlands
- Nejc Piko, Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia.
- Johannes Stegbauer, Department of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
- Claudia Torino, Institute of Clinical Physiology, National Research Council, Reggio Calabria, Italy
- Amaryllis Van Craenenbroeck, Department of Nephrology, University Hospitals Leuven, Leuven, Belgium

### Invited speakers:

- Esteban Porrini. Faculty of Medicine, University of La Laguna, Tenerife, Spain
- Charles Ferro. Institute of Cardiovascular Sciences, University of Birmingham and Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, United Kingdom
- Pantelis Sarafidis, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Justo Sandino, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.
- Marina López, Nephrology Department, Hospital Vall d'Hebron and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
- Clara Barrios, Department of Nephrology, Hospital del Mar, Barcelona, Spain
- Maria Jose Soler, Nephrology Department, Hospital Vall d'Hebron and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
- Manuela Abbate, Universitat de les Illes Balears, Palma de Mallorca, Illes Balears, Spain